Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines
about
Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancerCetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer TherapyThe development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.Effects of olive oil polyphenols on fatty acid synthase gene expression and activity in human colorectal cancer cells.Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical originsEnhancement of oxaliplatin-induced cell apoptosis and tumor suppression by 3-methyladenine in colon cancerControlling murine and rat chronic pain through A3 adenosine receptor activation5-Hydroxy-7-Methoxyflavone Triggers Mitochondrial-Associated Cell Death via Reactive Oxygen Species Signaling in Human Colon Carcinoma Cells.NADPH oxidase biology and the regulation of tyrosine kinase receptor signaling and cancer drug cytotoxicityRole of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase.Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic painBafilomycin A1 triggers proliferative potential of senescent cancer cells in vitro and in NOD/SCID mice.Recently identified and potential targets for colon cancer treatment.Why do targeted agents not work in the adjuvant setting in colon cancer?Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Strawberry-Tree Honey Induces Growth Inhibition of Human Colon Cancer Cells and Increases ROS Generation: A Comparison with Manuka Honey.Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis.Contribution of in vitro comparison of colorectal carcinoma cells from primary and metastatic lesions to elucidation of mechanisms of tumor progression and response to anticancer therapy.Panitumumab-Conjugated Pt-Drug Nanomedicine for Enhanced Efficacy of Combination Targeted Chemotherapy against Colorectal Cancer.Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array'Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy.Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway.Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features.Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells.FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer.
P2860
Q26747335-7DAD6DE6-16AC-41E6-AE45-B98D5562047DQ33829760-A7CA9BB5-EB6C-4BE7-AB01-396D1471CA67Q33862425-BD047AA7-F7AA-4821-BBA6-20F90685F1CAQ33947251-28879AED-210B-40A4-BB53-A0759F529FAAQ34581630-2A116CB7-A7EC-422C-8D28-E2C23D8E8DF0Q34831682-C5A4C3C1-8AB7-45E1-B230-93245B24C7FFQ35742126-4D57B4B6-86E6-43AD-AA3F-4DEAD348412FQ35913037-4B7582EC-5D1D-4D28-9CD1-603286B4418FQ35999628-69ADB7AB-5F09-4D3C-82A2-7AB47A0D3B2FQ36656128-AF62D412-D7BC-4332-B47B-F4B950125E33Q36895532-EDC70D27-5178-4BB8-94DD-AA5536B05BC1Q36909043-21812C7D-74F9-4E42-BE00-0A27B7461F53Q37117256-467F46B6-C670-4334-91AC-F0C8230377F4Q37705958-8A0E6F62-6936-4975-BA3D-DA05B995AD76Q37763104-2DF818C4-5331-43A2-BBCD-8D30785EAC71Q38062021-626613F1-10EA-45DF-8B0D-5FFA1981AB10Q38071119-32670119-1AB5-4BF6-BA0E-4FF25E142D67Q38712474-5F6B34EF-D838-4CC3-89B5-9EC6DC5D1C3EQ38755440-0806D726-64F7-443F-A454-73CE5B61B404Q38801368-A15DDCE1-A0AD-4376-B7BC-00D01C478798Q38832881-9612866F-209D-4AB0-8100-A4121430CA30Q42755426-E21D59B8-1376-4127-8A33-834CB9C7E7FDQ46225923-0D26AC1C-FC28-45DB-9F52-2162D66C4099Q46329298-AFE2EFB5-2B13-420D-BFEE-FC923FD57782Q47133723-14AE4413-C098-4EF0-B654-A1DB96AD83BEQ47624450-1643B19A-2640-4A25-932E-185D58C01411Q49513925-B9D7334A-35B6-4EA9-A9D9-C7472B30697AQ52666988-27056482-C892-4279-974B-2D22DC6C40CEQ53762655-5713FF50-CA59-49B6-96C6-1D0ED700F092
P2860
Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Modulation of cellular redox s ...... n colorectal cancer cell lines
@en
Modulation of cellular redox s ...... colorectal cancer cell lines.
@nl
type
label
Modulation of cellular redox s ...... n colorectal cancer cell lines
@en
Modulation of cellular redox s ...... colorectal cancer cell lines.
@nl
prefLabel
Modulation of cellular redox s ...... n colorectal cancer cell lines
@en
Modulation of cellular redox s ...... colorectal cancer cell lines.
@nl
P2093
P2860
P1476
Modulation of cellular redox s ...... n colorectal cancer cell lines
@en
P2093
Amine Sadok
Jean François Seitz
Jean-Louis Formento
Laetitia Dahan
P2860
P304
P356
10.1111/J.1476-5381.2009.00341.X
P407
P577
2009-09-01T00:00:00Z